Neuro-Oncology News

Noncommunicable neurological disorders resulted in “a large and increasing burden” in the United States, according to a systematic analysis of the Global Burden of Disease study from 2017 that was published in JAMA Neurology.

Stereotactic radiosurgery conferred equivalent OS as whole-brain radiation but with less cognitive decline in patients with four or more nonmelanoma brain metastases, according to study results presented at the virtual ASTRO Annual Meeting.

In this video from the Annual Meeting of the American Neurological Association, David Gutmann, MD, PhD, FAAN, discusses the plenary session he co-chaired with Steven Small, MD, PhD, on microenvironment control of brain tumor pathogenesis.

Opioids are a potent pharmacologic option for managing recurrent pain experienced by cancer survivors.

The FDA granted fast track designation to paxalisib for the treatment of patients with newly diagnosed glioblastoma, according to a manufacturer-issued press release.

An unsupervised, automated machine learning algorithm successfully identified glioblastoma tumor cells and stratified survival outcomes, according to study results published in eLife.

The FDA granted fast track designation to enzastaurin for the treatment of patients with newly diagnosed glioblastoma, according to a press release from the agent’s manufacturer.

The FDA granted fast track designation to TVI-Brain-1, an adoptive T cell therapy for the treatment of glioblastoma multiforme, according to the agent’s manufacturer.

Chimeric antigen receptor T-cell therapies have demonstrated limited antitumor activity in glioblastoma. Although the therapies have been tolerable, response rates have been low and responses lack durability.

Risk for suicide appeared higher among individuals within the first year of a brain cancer diagnosis compared with the general population, according to a research letter published in JAMA Network Open.